{"filings":[{"id":554239,"accession_number":"0001193125-26-232533","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-20T20:04:03+00:00","items":["8.01"],"status":"ready","headline":"CMS expands Medicare coverage for Personalis's NeXT Personal test to monitor neoadjuvant therapy in breast cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.","Expansion effective May 19, 2026, under CMS Molecular Diagnostics Program.","NeXT Personal is an ultrasensitive liquid biopsy test; this indication broadens addressable patient population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69961,"accession_number":"0001193125-26-221846","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-13T20:52:20+00:00","items":["5.07"],"status":"ready","headline":"Personalis stockholders elect directors, ratify auditor, approve exec compensation at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olivia K. Bloom and Woodrow A. Myers, Jr., M.D. elected as Class I directors for three-year terms.","Ratification of BDO USA, P.C. as independent auditor for FY 2026: 91,586,300 for, 34,421 against.","Non-binding advisory vote on named executive officer compensation passed: 75,549,455 for, 384,918 against.","Quorum of 91,869,300 shares (87.76%) present at May 12, 2026 virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67884,"accession_number":"0001193125-26-221574","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-13T20:03:04+00:00","items":["8.01"],"status":"ready","headline":"CMS expands Medicare coverage for Personalis' NeXT Personal test to immunotherapy monitoring","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS coverage now includes immunotherapy monitoring for late-stage solid tumor patients as of May 12, 2026.","NeXT Personal is an ultrasensitive liquid biopsy test; the expanded indication broadens the addressable patient population.","No financial impact or revenue guidance was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93445,"accession_number":"0001193125-26-211850","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.","Cash, equivalents & short-term investments $233.2M; includes ~$21M net from ATM at $10.00/share.","Full-year 2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45k, net loss ~$105M.","Second Medicare coverage in six months (lung cancer surveillance) follows prior breast cancer win.","CEO states 'Win-in-MRD' strategy working; clinical revenue expected to grow five-fold in 2026."],"consensus_eps_estimate":-0.2751,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":15472000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105064,"accession_number":"0001193125-26-110852","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Personalis appoints Richard Chen as President; CEO Hall steps down from President role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Chen appointed President effective March 13, 2026; he retains EVP R&D and CMO roles.","Annual base salary raised to $570,000 effective April 1, 2026; performance bonus target increased to 70% of base.","Granted option to purchase 37,500 shares (closing price on March 13, 2026) vesting over 36 months.","Granted RSU award of 6,250 shares vesting one-sixth at six-month anniversary, then bi-annually thereafter.","Christopher Hall, CEO, previously held President role; no other changes to Board or executive team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105063,"accession_number":"0001193125-26-076553","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.","Total FY2025 revenue $69.6M (down 18% YoY); clinical test revenue more than doubled to $2.0M.","Ended 2025 with ~$240M cash, including $109M net from ATM at $8.43/share average.","Secured Medicare coverage for breast and lung cancer surveillance; key catalyst for MRD.","FY2026 guidance: total revenue $78-80M, clinical revenue $10-11M (5x growth), net loss ~$105M."],"consensus_eps_estimate":-0.299,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":69648000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105062,"accession_number":"0001193125-26-007037","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).","Clinical test volume of 16,233 in FY2025, up ~400% YoY; Q4 alone 6,183 tests (+41% vs Q3).","Clinical test revenue doubled to ~$2.0M in FY2025 (2024: $0.8M).","Cash, equivalents, and short-term investments ~$240M, including $109M from ATM at $8.43/share.","Secured Medicare coverage for breast cancer surveillance, a key reimbursement milestone."],"consensus_eps_estimate":-0.299,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":69648000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121316,"accession_number":"0001193125-25-302644","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Personalis files prospectus supplement for up to $100M at-the-market stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100 million of common stock may be sold under amended ATM sales agreement with Piper Sandler and BTIG.","Offering is in addition to the existing ATM facility from December 2024.","Cooley LLP legal opinion on the shares is filed as Exhibit 5.1.","Proceeds intended for general corporate purposes, no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121315,"accession_number":"0001193125-25-294454","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025","Reimbursement for NeXT Personal Single Plasma Test set at $1,164, available up to six years post-treatment","Medicare coverage for the NeXT Personal Dx test is available once per cancer diagnosis for stage II/III breast cancer"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121314,"accession_number":"0001193125-25-273416","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.","Reimbursement rate $3,878 for NeXT Personal Dx Breast MRD test; $1,158 for NeXT Personal Single Plasma Test.","Coverage effective retroactively from October 7, 2025; Single Plasma test available up to 6 years post-treatment.","Dx Breast MRD test covered once per cancer diagnosis; expands market access for Personalis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121313,"accession_number":"0001193125-25-264690","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.","Delivered 4,388 clinical tests, +26% sequential and +364% YoY; submitted third Medicare dossier for lung cancer.","FY 2025 revenue guidance narrowed to $68-73M (from $70-80M); clinical tests reimbursed cut to $1.5-2M from $3-6M.","Cash, cash equivalents and investments $150.5M; cash used in operations and capex $23.4M in Q3.","Q4 2025 revenue outlook $15.7-20.7M; pharma/services revenue $12-17M; population sequencing ~$3.7M."],"consensus_eps_estimate":-0.2842,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":52303000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137972,"accession_number":"0000950170-25-110739","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives $13.5M new task order under VA Million Veteran Program contract","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New task order effective Sept 30, 2025, valued up to $13.5M subject to sample receipt and service performance.","Cumulative value of all task orders under VA MVP contracts now approximately $225.0M.","Contract with U.S. Department of Veterans Affairs for Million Veteran Program continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137971,"accession_number":"0001193125-25-173575","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Reports Q2 2025 Revenue of $17.2M, Net Loss $20.1M; Clinical Test Volume Up 59% Sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.","Revenue decreased 24% to $17.2M from $22.6M in Q2 2024, partly due to $5.6M decline from Natera.","Net loss was $20.1M ($0.23 per share) versus $12.8M ($0.24 per share) in Q2 2024.","Expanded Tempus AI collaboration to include colorectal cancer for exclusive commercialization.","Lowered full-year 2025 revenue guidance to $70-80M from $80-90M, citing biopharma headwinds."],"consensus_eps_estimate":-0.2486,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":37808000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137970,"accession_number":"0001193125-25-157096","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.","Agreement term extended to November 25, 2029.","Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.","Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155357,"accession_number":"0000950170-25-074346","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Personalis annual meeting: directors elected, auditor ratified, say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["A. Blaine Bowman elected as Class III director with 58.2M for, 710K withheld; Karin Eastham with 53.7M for, 5.2M withheld.","Ratification of BDO USA as auditor for FY2025: 76.6M for, 110K against, 112K abstentions.","Advisory vote on named executive officer compensation approved: 56.6M for, 2.2M against, 38K abstentions.","Quorum of 87.0% of outstanding shares (76.8M of 88.3M) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155356,"accession_number":"0001193125-25-113820","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).","Net loss $15.8M ($0.18/share) vs $13.0M ($0.26) in Q1 2024; per-share improved on higher share count.","Clinical test volume 2,184, up 52% from Q4 2024; NeXT Personal data in CRC and breast cancer submitted for Medicare.","Raised $17.8M net from ATM at $5.89/share; cash $185.7M; operations cash use $20.5M.","FY2025 revenue guidance unchanged $80-90M; gross margin raised to 22%-24%; net loss guidance narrowed to ~$83M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":20605000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173872,"accession_number":"0001193125-25-039219","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.","Q4 revenue $16.8M (-15% YoY); delivered 1,441 molecular tests in Q4 (+52% QoQ); FY24 tests 3,285 vs 177 in FY23.","Guidance: FY25 revenue $80-90M, gross margin 21-23%, net loss ~$85M, cash usage $75-80M (up from $47M in FY24).","Business highlights: submitted for Medicare coverage in early-stage breast cancer; multi-year Moderna extension; expanded Tempus deal."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":84614000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173871,"accession_number":"0001193125-25-002872","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.","Pharma/enterprise/other revenue grew 20% to ~$77.2M despite Natera revenue declining 20% to ~$25.4M.","Q4 revenue of ~$16.8M (down 15% YoY); delivered 1,441 molecular tests, up 52% from Q3.","Cash, cash equivalents, and short-term investments of ~$185.0M, including $50M strategic investment from Merck; path to cash flow break-even."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":84614000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190842,"accession_number":"0001193125-24-285922","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Personalis enters amended ATM equity sales agreement with Piper Sandler and BTIG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended and Restated ATM Sales Agreement dated Dec 27, 2024 with Piper Sandler & Co. and BTIG, LLC as sales agents.","Company may offer and sell shares of common stock from time to time through the agents under the ATM program.","Prospectus supplement filed to shelf registration statement (Form S-3) relating to the offering of shares.","Previous sales agreement prospectus from January 2024 terminated; no further offers under that program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190841,"accession_number":"0001193125-24-281696","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.","Merck receives standstill, information, pro-rata participation, and voting rights until 2 years post-close.","Tempus AI authorized to sell NeXT Personal minimal residual disease test to pharma/biotech clients.","Moderna extends SOW for V940/mRNA-4157 INT program to up to 10 years; Moderna can license IP for low double-digit millions.","Personalis to use $10M of proceeds to open ISO-certified lab outside US, mutually agreed with Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190840,"accession_number":"0000950170-24-122230","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).","Net loss $39.1M includes $26.0M non-cash warrant expense; cash $143.7M.","Raised FY2024 revenue guidance to $83-84M from $79-81M; Q4 revenue expected $15-16M.","Delivered 945 molecular tests in Q3, a 68% sequential increase.","Raised ~$62.2M net from Tempus warrant exercise and ATM stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":67814000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207322,"accession_number":"0000950170-24-108191","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Personalis receives $7.5M new task order from VA Million Veteran Program; cumulative orders reach $210.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New task order under VA Million Veteran Program contract effective Sept. 30, 2024, valued up to $7.5M.","Cumulative task order value under VA MVP contracts now approximately $210.7 million.","Revenue recognition subject to receipt of samples from VA and performance of services by Personalis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207321,"accession_number":"0001193125-24-201697","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Tempus invests $36M in Personalis, exercises warrants and buys shares; expands commercial collaboration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tempus exercises warrants for 9.2M shares at avg $2.00 ($18.4M) and buys 3.5M shares at $5.07 ($17.7M).","Total investment ~$36M; Tempus will own ~19.3% of Personalis outstanding common stock.","Partners accelerate commercialization of ultra-sensitive MRD testing for breast, lung, and immunotherapy monitoring.","Personalis to increase patient sample capacity; Tempus expands commercialization efforts over first two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207320,"accession_number":"0000950170-24-092712","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).","Net loss $12.8M, improved from $24.0M loss in Q2 2023; cash $87.0M.","FY 2024 revenue guidance raised to $79-81M from $76-78M; non-GAAP net loss ~$75M.","Cross-license agreement with Myriad Genetics; settled IP lawsuit with Foresight Diagnostics.","Delivered 561 molecular tests in Q2, up 66% QoQ; launched NeXT Personal Dx with Tempus AI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":42105000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224725,"accession_number":"0000950170-24-078618","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Personalis settles patent litigation with Foresight, grants license for MRD tests, receives tiered royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settled pending infringement claims and IPR proceedings with Foresight Diagnostics.","Foresight gets non-exclusive license under Personalis patents for WGS-based MRD tests using phased variants.","Foresight to pay low-single digit tiered royalty on net sales of licensed products/services.","Upon a change of control involving specified acquirers, a low single-digit million one-time fee and slight royalty rate increase apply.","License is perpetual except for patent challenge termination; each party releases claims and covenants not to sue on CNS patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224724,"accession_number":"0000950170-24-062886","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Personalis annual meeting: directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christopher Hall, Lonnie Shoff, Kenneth J. Widder elected Class II directors until 2027.","BDO USA ratified as independent auditor for FY2024 with 40,946,872 votes for.","Advisory say-on-pay on named executive officers passed with 25,393,708 votes for.","Broker non-votes of 15,492,304 shares on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224723,"accession_number":"0000950170-24-055585","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.","Net loss narrowed to $13.0M from $28.7M in Q1 2023, aided by $4.8M non-cash gain on Tempus warrants.","Raised FY2024 total revenue guidance to $76-78M from $73-75M; non-GAAP net loss improved to ~$77M from prior ~$80M.","Cash and short-term investments $95.4M; Q2 2024 revenue expected $19.5-20.5M.","NeXT Personal MRD test published in Oncotarget; 338 molecular tests delivered; five ASCO abstracts accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":19525000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243993,"accession_number":"0000950170-24-022032","cik":1527753,"company_name":"Personalis, Inc.","ticker":"PSNL","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Personalis Q4 revenue $19.7M (+18% YoY); FY2024 revenue guidance $73-75M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $19.7M (+18% YoY); FY2023 revenue $73.5M (+13% YoY).","Q4 net loss $26.6M ($0.54 EPS); FY net loss $108.3M ($2.25 EPS).","FY2024 guidance: revenue $73-75M, net loss ~$80M (down from $108.3M), cash usage ~$62M.","Obtained final Medicare coverage for NeXT Dx tumor profiling test; partnerships with Tempus, Myriad, ClearNote, and Natera extension."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":73481000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1106901999.1548998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}